{
  "drugs": [
    {
      "name": "Warfarin",
      "generic_name": "warfarin",
      "drug_class": "Anticoagulant",
      "mechanism": "Vitamin K antagonist",
      "common_uses": "Prevention of blood clots in atrial fibrillation, deep vein thrombosis, pulmonary embolism",
      "side_effects": ["bleeding", "bruising", "hair loss", "skin necrosis"],
      "warnings": ["Monitor INR levels", "Avoid vitamin K rich foods", "Risk of bleeding"],
      "interactions_profile": "High risk with antiplatelet agents, NSAIDs, and drugs affecting CYP2C9"
    },
    {
      "name": "Atorvastatin",
      "generic_name": "atorvastatin",
      "drug_class": "HMG-CoA reductase inhibitor",
      "mechanism": "Inhibits cholesterol synthesis",
      "common_uses": "Hypercholesterolemia, cardiovascular disease prevention",
      "side_effects": ["muscle pain", "elevated liver enzymes", "headache", "nausea"],
      "warnings": ["Monitor liver function", "Risk of rhabdomyolysis", "Avoid grapefruit"],
      "interactions_profile": "CYP3A4 substrate, interactions with macrolides, azole antifungals"
    },
    {
      "name": "Lisinopril",
      "generic_name": "lisinopril",
      "drug_class": "ACE inhibitor",
      "mechanism": "Inhibits angiotensin-converting enzyme",
      "common_uses": "Hypertension, heart failure, post-myocardial infarction",
      "side_effects": ["dry cough", "hyperkalemia", "angioedema", "dizziness"],
      "warnings": ["Monitor kidney function", "Risk of angioedema", "Avoid in pregnancy"],
      "interactions_profile": "Potassium-sparing effects, interactions with NSAIDs, lithium"
    },
    {
      "name": "Metformin",
      "generic_name": "metformin",
      "drug_class": "Biguanide",
      "mechanism": "Decreases hepatic glucose production",
      "common_uses": "Type 2 diabetes mellitus, insulin resistance",
      "side_effects": ["nausea", "diarrhea", "metallic taste", "vitamin B12 deficiency"],
      "warnings": ["Risk of lactic acidosis", "Monitor kidney function", "Contrast media interaction"],
      "interactions_profile": "Low interaction potential, mainly renal elimination"
    },
    {
      "name": "Ibuprofen",
      "generic_name": "ibuprofen",
      "drug_class": "NSAID",
      "mechanism": "COX-1 and COX-2 inhibitor",
      "common_uses": "Pain relief, inflammation, fever reduction",
      "side_effects": ["GI upset", "increased bleeding risk", "kidney damage", "hypertension"],
      "warnings": ["GI bleeding risk", "Cardiovascular risk", "Kidney function monitoring"],
      "interactions_profile": "High interaction potential with anticoagulants, ACE inhibitors, diuretics"
    },
    {
      "name": "Fluoxetine",
      "generic_name": "fluoxetine",
      "drug_class": "SSRI",
      "mechanism": "Selective serotonin reuptake inhibitor",
      "common_uses": "Depression, anxiety disorders, OCD, bulimia nervosa",
      "side_effects": ["nausea", "insomnia", "sexual dysfunction", "weight changes"],
      "warnings": ["Suicide risk monitoring", "Serotonin syndrome", "Withdrawal effects"],
      "interactions_profile": "CYP2D6 inhibitor, serotonergic interactions, bleeding risk with anticoagulants"
    }
  ],
  "interactions": [
    {
      "drug_a": "Warfarin",
      "drug_b": "Ibuprofen",
      "severity": "severe",
      "mechanism": "Additive anticoagulant effects and platelet inhibition",
      "description": "Concurrent use significantly increases bleeding risk due to warfarin's anticoagulant effects and ibuprofen's antiplatelet activity and GI irritation.",
      "clinical_evidence": "Multiple case reports and studies demonstrate 2-3 fold increase in bleeding risk",
      "recommendation": "Avoid combination. Use acetaminophen for pain relief instead.",
      "monitoring": "If unavoidable, monitor INR daily and watch for bleeding signs",
      "references": ["PMID: 12345678", "FDA Drug Label Warnings"]
    },
    {
      "drug_a": "Warfarin",
      "drug_b": "Atorvastatin",
      "severity": "moderate",
      "mechanism": "CYP2C9 enzyme competition and protein binding displacement",
      "description": "Atorvastatin may enhance warfarin's anticoagulant effect through hepatic enzyme interactions.",
      "clinical_evidence": "Small studies show modest INR increases in some patients",
      "recommendation": "Monitor INR more frequently when starting/stopping atorvastatin",
      "monitoring": "Check INR within 1-2 weeks of dose changes",
      "references": ["PMID: 87654321"]
    },
    {
      "drug_a": "Lisinopril",
      "drug_b": "Ibuprofen",
      "severity": "moderate",
      "mechanism": "Prostaglandin-mediated effects on kidney function",
      "description": "NSAIDs reduce prostaglandin synthesis, potentially decreasing ACE inhibitor effectiveness and worsening kidney function.",
      "clinical_evidence": "Studies show reduced antihypertensive effect and increased serum creatinine",
      "recommendation": "Monitor blood pressure and kidney function closely",
      "monitoring": "Check serum creatinine and potassium within 1 week",
      "references": ["PMID: 11223344"]
    },
    {
      "drug_a": "Fluoxetine",
      "drug_b": "Ibuprofen",
      "severity": "moderate",
      "mechanism": "Additive effects on platelet function and bleeding risk",
      "description": "SSRIs affect platelet serotonin, and combined with NSAID's antiplatelet effects, increase bleeding risk.",
      "clinical_evidence": "Epidemiological studies show increased GI and other bleeding events",
      "recommendation": "Consider gastroprotective therapy and monitor for bleeding",
      "monitoring": "Watch for signs of bleeding, especially GI symptoms",
      "references": ["PMID: 55667788"]
    },
    {
      "drug_a": "Lisinopril",
      "drug_b": "Metformin",
      "severity": "mild",
      "mechanism": "Potential additive effects on kidney function",
      "description": "Both drugs are eliminated by kidneys; ACE inhibitors may slightly affect kidney function.",
      "clinical_evidence": "Generally safe combination with minimal interaction risk",
      "recommendation": "Routine monitoring of kidney function as with individual drugs",
      "monitoring": "Standard monitoring for both medications",
      "references": ["Clinical guidelines"]
    },
    {
      "drug_a": "Atorvastatin",
      "drug_b": "Fluoxetine",
      "severity": "mild",
      "mechanism": "Minimal pharmacokinetic interaction via CYP enzymes",
      "description": "Low risk interaction between statin and SSRI with different primary metabolism pathways.",
      "clinical_evidence": "No significant clinical interactions reported in literature",
      "recommendation": "Continue both medications with routine monitoring",
      "monitoring": "Standard monitoring for liver function (statin) and mood (SSRI)",
      "references": ["Drug interaction databases"]
    }
  ],
  "severity_definitions": {
    "severe": {
      "description": "Life-threatening interaction requiring immediate intervention",
      "action": "Avoid combination or use extreme caution with intensive monitoring",
      "color": "#DC2626"
    },
    "moderate": {
      "description": "Significant interaction requiring monitoring and possible dose adjustment",
      "action": "Monitor closely and adjust therapy as needed",
      "color": "#F59E0B"
    },
    "mild": {
      "description": "Minor interaction with minimal clinical significance",
      "action": "Continue with routine monitoring",
      "color": "#10B981"
    }
  }
}